These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1720417)

  • 21. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
    Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
    Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function.
    Holländer GA; Bierer BE; Burakoff SJ
    Transfus Sci; 1994 Sep; 15(3):207-20. PubMed ID: 10155542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro.
    Morita H; Takeda K; Yagita H; Okumura K
    Biochem Biophys Res Commun; 1999 Oct; 264(2):321-6. PubMed ID: 10529362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rapamycin on the expression of the IL-2 receptor (CD25).
    Woerly G; Brooks N; Ryffel B
    Clin Exp Immunol; 1996 Feb; 103(2):322-7. PubMed ID: 8565319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion.
    Eugui EM; Almquist SJ; Muller CD; Allison AC
    Scand J Immunol; 1991 Feb; 33(2):161-73. PubMed ID: 1826793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL.
    Migita K; Origuchi T; Kawabe Y; Tominaga M; Ida H; Kawakami A; Eguchi K
    Transplantation; 1999 Oct; 68(7):1018-23. PubMed ID: 10532544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1.
    Almawi WY; Assi JW; Chudzik DM; Jaoude MM; Rieder MJ
    Cell Transplant; 2001; 10(7):615-23. PubMed ID: 11714196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects.
    Rauch MC; San Martín A; Ojeda D; Quezada C; Salas M; Cárcamo JG; Yañez AJ; Slebe JC; Claude A
    Transpl Immunol; 2009 Dec; 22(1-2):72-81. PubMed ID: 19628039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level.
    Andersson J; Nagy S; Groth CG; Andersson U
    Immunology; 1992 Jan; 75(1):136-42. PubMed ID: 1371491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
    Hess DA; Bird IA; Almawi WY; Rieder MJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli.
    Karlsson H; Nässberger L
    Transplantation; 1997 Oct; 64(8):1217-20. PubMed ID: 9355847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Energy levels in resting and mitogen-stimulated human lymphocytes during treatment with FK506 or cyclosporin A in vitro.
    Karlsson H; DePierre JW; Nässberger L
    Biochim Biophys Acta; 1997 Apr; 1319(2-3):301-10. PubMed ID: 9131051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporin A inhibits induction of IL-2 receptor alpha chain expression by affecting activation of NF-kB-like factor(s) in cultured human T lymphocytes.
    Brini AT; Harel-Bellan A; Farrar WL
    Eur Cytokine Netw; 1990; 1(3):131-9. PubMed ID: 2129797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.
    Yoshimura N; Matsui S; Hamashima T; Oka T
    Transplantation; 1989 Feb; 47(2):356-9. PubMed ID: 2465593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system.
    Tsuji RF; Yamamoto M; Nakamura A; Kataoka T; Magae J; Nagai K; Yamasaki M
    J Antibiot (Tokyo); 1990 Oct; 43(10):1293-301. PubMed ID: 1701765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.
    Woo J; Propper DJ; Macleod AM; Thomson AW
    Clin Exp Immunol; 1990 Dec; 82(3):462-8. PubMed ID: 1702375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity.
    Yoshimura N; Matsui S; Hamashima T; Lee CJ; Oka T
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1045-7. PubMed ID: 2468202
    [No Abstract]   [Full Text] [Related]  

  • 39. The actions of cyclosporin A and FK506 on T-lymphocyte activation.
    Mattila PS
    Biochem Soc Trans; 1996 Feb; 24(1):45-9. PubMed ID: 8674715
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.
    Hess AD; Bright EC
    Transplantation; 1991 Jun; 51(6):1232-40. PubMed ID: 1646506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.